---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-23-000016"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:09:55.005548+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ANI Pharma Q2 revenue $116.5M (+57.8% YoY); raises FY2023 guidance

## Summary
- Record Q2 net revenues of $116.5M (up 57.8% YoY); GAAP diluted EPS $0.29 vs $(0.94) loss in Q2 2022.
- Adjusted non-GAAP EBITDA $34.1M (up 246% YoY); adjusted diluted EPS $1.28 vs $0.13.
- Cortrophin Gel net sales $24.3M (+138.2% YoY); record new patient starts and prescribers.
- Raised FY2023 guidance: net revenue $425M-$445M (from $385M-$410M); adj. EBITDA $115M-$125M.
- Ended Q2 with $161.7M cash; completed equity offering with $80.6M net proceeds.

## SEC filing metadata
- accession: 0001023024-23-000016
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302423000016/0001023024-23-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302423000016/ani-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-23-000016
- JSON: https://secwatch.observer/filing/0001023024-23-000016.json
- Plain text: https://secwatch.observer/filing/0001023024-23-000016.txt

## Key facts
- Earnings Releases
  ANI PHARMACEUTICALS INC reported Q2 2023 results: revenue $116.5 million, net income $5.8 million, EPS $0.29. Guidance raised.
  - Period: Q2 2023
  - Revenue: $116.5 million
  - Net income: $5.8 million
  - EPS: $0.29
  - Guidance: raised
  - Result: reported results
  source text: Pharmaceuticals Reports Record Second Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance Second Quarter 2023 Financial Results -- Record quarterly net revenues of $116.5 million, representing year-over-year growth of 57.8%; net income available to common shareholders of $5.8 million and diluted GAAP income per share of $0.29 -- -- Record quarterly
  evidence_url: https://www.sec.gov/Archives/edgar/data/1023024/000102302423000016/0001023024-23-000016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.